Determination of the Relationship Between Nesfatin-1 Levels and Energy Intake Levels of Patients With Type 2 Diabetes, Insulin Resistance and Obesity
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 180
- Locations
- 1
- Primary Endpoint
- Nefratin-1 in obesity
Study Overview
Brief Summary
This research was planned to determine the level of nesfatin-1, known as satiety hormone, in type 2 diabetes, insulin diabetes and obesity patients and to determine whether there is a relationship between patients' energy intake levels. Additionally, it was aimed to evaluate the relationship between patients' nesfatin-1 values and serum glucose, insulin, lipid concentrations.
Detailed Description
Nesfatin-1 levels of patients with type 2 diabetes, insulin resistance and obesity will be measured. In addition, patients' daily food consumption will be taken and the amount of energy they receive will be calculated daily. The relationship between the level of nesfatin-1 in the blood and the energy received will be examined.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Diagnostic
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 19 Years to 79 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Type 2 diabetes
- •Insulin resistance
- •Obesity disease
Exclusion Criteria
- •Pediatric individuals
- •All patients who are hospitalized,
- •Liver disease
- •Cancer patients
- •Disease related to the gastrointestinal tract
- •Nephrological disease such as chronic kidney failure, acute kidney failure, nephrotic syndrome
- •Neurological disease
Arms & Interventions
Type 2 Diabetes group
In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
Intervention: Nesfatin-1 (Diagnostic Test)
Insulin resistance group
In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
Intervention: Nesfatin-1 (Diagnostic Test)
Obesity group
In case of fasting, blood will be taken from patients for the measurement of nesfatin-1.
Intervention: Nesfatin-1 (Diagnostic Test)
Outcomes
Primary Outcomes
Nefratin-1 in obesity
Time Frame: 1 day (Blood will be drawn from patients once)
Blood will be drawn from obesity patients after 12 hours of fasting (n=45)
Nefratin-1 in insulin resistance
Time Frame: 1 day (Blood will be drawn from patients once)
Blood will be drawn from insulin resistance patients after 12 hours of fasting (n=45)
Nefratin-1 in type 2 diabetes
Time Frame: 1 day (Blood will be drawn from patients once)
Blood will be drawn from type 2 diabates patients after 12 hours of fasting (n=45)
Secondary Outcomes
No secondary outcomes reported
Investigators
Gülin Öztürk Özkan
Assistant Professor
Istanbul Medeniyet University